PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• PROteolysis TArgeting Chimeras (PROTACs) are emerging as a promising therapeutic strategy for cancer treatment.
• PROTACs are heterobifunctional molecules that induce targeted protein degradation via the ubiquitin-proteasome system.

Purpose of the Study:

• To review the potential of PROTACs as anticancer therapeutics.
• To discuss chemical and bioinformatics approaches for PROTAC design.
• To focus on developing tumor-specific PROTACs by targeting E3 ligases enriched in tumors.

Main Methods:

• Review of existing literature on PROTAC technology in cancer therapy.
• Analysis of chemical and bioinformatics strategies for PROTAC development.
• Discussion of safety concerns, particularly on-target toxicities.

Main Results:

• PROTACs have shown efficacy in degrading various cancer targets across multiple tumor types.
• Current PROTACs often use ubiquitously expressed E3 ligases, leading to potential toxicities.
• Targeting tumor-enriched E3 ligases offers a strategy for developing selective anticancer PROTACs.

Conclusions:

• PROTACs hold significant potential for cancer therapy.
• Developing tumor-specific PROTACs is crucial for improving safety and efficacy.
• Further research into tumor-specific E3 ligase recruitment is warranted for targeted cancer treatment.